Aikium
Aikium combines deep learning and wet-lab experimentation to develop protein therapeutics. · Health
How they use Nebius
Aikium combines deep learning with large-scale wet-lab experimentation to develop protein therapeutics. Its Yotta-ML² platform targets proteins considered difficult to treat with traditional approaches, including GPCRs and ion channels.
Aikium won the Drug Discovery category of the 2025 Nebius AI Discovery Awards. Nebius awarded category winners $100,000 in GPU credits for Nebius AI Cloud and granted participants inferencing credits for Nebius AI Studio. VAST Data reported that Aikium was deploying the awarded GPU cloud resources for drug discovery. Its account describes Aikium’s platform synthesizing and screening trillions of protein variants using mRNA display technology.
Sources
3 sourcesNebius announces AI Discovery Awards winners
Published 23 Jun 2025 · Nebius · Web page
Nebius names Aikium as the Drug Discovery winner and states that category winners receive AI Cloud GPU credits. All participants were also granted AI Studio inferencing credits.
Open original sourceAikium announces Nebius award
Published 18 Jun 2025 · Aikium · Web page
Aikium announces its Nebius AI Discovery Award in Drug Discovery for work using its Yotta-ML² platform.
Open original sourceCompany context
aikium.comAikium, operated by Aikium Inc., develops protein therapeutics by combining deep learning with large-scale laboratory screening. Its Yotta-ML² platform designs and tests protein libraries against difficult disease targets, including GPCRs and ion channels. The company works with research organizations, including cancer hospitals, to advance drug discovery. Its technology includes SeqR non-antibody scaffold proteins designed to bind disordered protein regions. Aikium also presents a protein engineering suite comprising Aiki, Aiki-Sol, Aiki-XP and Aiki-GeNano for protein discovery and development workflows.